In Canada news:
The safety of the asthma drug Xolair is under review to investigate a potential link to cardiovascular problems.
The probe was triggered by interim findings in an ongoing U.S. study into the long-term safety of Xolair, known generically as omalizumab.
The early data point to a disproportionate increase in cardiovascular problems among people treated with Xolair compared with those who did not take the drug. The reported problems include heart attacks, abnormal heart rhythms, heart failure, fainting, mini-strokes and blood clots.
That's part of an article you can find here.
